PARP inhibition has been shown to lead to an accumulation of DNA strand breaks, and is believed to be particularly effective in patients with ovarian cancer who have mutations in the BRCA1 or BRCA2 tumor suppressor genes since those molecular alterations are also associated with impairment of homologous recombination in DNA repair. Here, BRCA1 is linked to ovarian cancer.